Intraoperative radiotherapy with electrons: fundamentals, results, and innovation

15 Aug 2013
FA Calvo, CV Sole, R Herranz, M Lopez-Bote, J Pascau, A Santos, A Muñoz-Calero, C Ferrer, JL Garcia-Sabrido

Rationale and objectives: To analyse the programme activity and clinical innovation and/or technology developed over a period of 17 years with regard to the introduction and the use of intraoperative radiotherapy (IORT) as a therapeutic component in a medical–surgical multidisciplinary cancer hospital.

Material and methods: To standardise and record this procedure, the Radiation Oncology service has an institutional programme and protocols that must be completed by the different specialists involved. For 17 years, IORT procedures were recorded on a specific database that includes 23 variables with information recorded on institutional protocols. As part of the development and innovation activity, two technological tools were implemented (RADIANCE and MEDTING) in line with the standardisation of this modality in clinical practice.

Results: During the 17 years studied, 1,004 patients were treated through 1,036 IORT procedures. The state of the disease at the time of IORT was 77% primary and 23% recurrent. The origin and distribution of cancers were 62% gastrointestinal, 18% sarcomas, 5% pancreatic, 2% paediatric, 3% breast, 7% less common locations, and 2% others. The research and development projects have generated a patent on virtual planning (RADIANCE) and proof of concept to explore as a professional social network (MEDTING).

During 2012, there were 69 IORT procedures. There was defined treatment volume (target or target region) in all of them, and 43 were conducted by the virtual planning RADIANCE system. Eighteen have been registered on the platform MEDTING as clinical cases.

Conclusion: The IORT programme, developed in a university hospital with an academic tradition, and interdisciplinary surgical oncology, is a feasible care initiative, able to generate the necessary intense clinical activity for tending to the cancer patient. Moreover, it is a competitive source for research, development, and scientific innovation.

Related Articles

Mariana Serrano, Jhajaira M Araujo, Cristian Pacheco, Jackeline Macetas, Mariella A Blum, Alfredo Carrato, Eloy Ruiz, Francisco Berrospi, Carlos Luque, Ivan Chavez, Eduardo Payet, Luis Taxa, Paola Montenegro
Arun Sankar Sudha, Ravikumar Rejnish Kumar, Milan Anjanappa, Cessal Thomas Kainickal, Aleyamma Mathew, Ramadas Kunnambath
Goutam Panda, Arun Chandrasekharan, Shasanka Das, Prabhat Bhargava, Sujay Srinivas, Siddhartha Laskar, Smruti Mokal, Bharat Rekhi, Nehal Khanna, Nandini Menon, Vijay Patil, Vanita Noronha, Amit Joshi, Kumar Prabhash, Shripad D Banavali, Sudeep Gupta, Jyoti Bajpai
Simone de Campos Vieira Abib, Chan Hon Chui, Sharon Cox, Abdelhafeez H Abdelhafeez, Israel Fernandez-Pineda, Ahmed Elgendy, Jonathan Karpelowsky, Pablo Lobos, Marc Wijnen, Jörg Fuchs, Andrea Hayes, Justin T Gerstle
Francisco Pimentel Cavalcante, Felipe Zerwes, Eduardo Camargo Millen, Guilherme Novita, Alessandra Borba Anton de Souza, João Henrique Penna Reis, Helio Rubens de Oliveira Filho, Luciana Naíra de B L Limongi, Barbara Pace Silva de Assis Carvalho, Adriana Magalhães de Oliveira Freitas, Monica Travassos Jourdan, Vilmar Marques de Oliveira, Ruffo Freitas-Junior